Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA

Clinical Trials & Research

September 28, 2020 — Khondrion, a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease, today announces that it received a rare pediatric disease (RPD) designation from the United States (US) Food and Drug Administration (FDA) for sonlicromonal for the treatment of patients with MELAS syndrome.

Sonlicromanol is Khondrion’s wholly-owned, potentially first-in-class oral small molecule and one of the most clinically-advanced disease-modifying drug treatments for mitochondrial disease in development. Currently in Phase IIb clinical development,  sonlicromanol has already been granted Orphan Drug Designations for MELAS, Leigh disease and patients with maternally inherited diabetes and deafness (MIDD) syndrome in Europe, and for all inherited mitochondrial respiratory chain disorders in the US.

The FDA grants RPD designation for serious and life-threatening diseases that primarily affect children aged 18 years or younger and fewer than 200,000 people in the United States. Subject to FDA approval of sonlicromanol for the treatment of MELAS syndrome, Khondrion may be granted a priority review voucher from the FDA that can be redeemed to obtain priority review for any subsequent marketing application or be sold or transferred to another company.

Prof. Dr. Jan Smeitink, Chief Executive Officer at Khondrion, said: “ We are delighted to have received this rare pediatric disease designation for our lead clinical stage development program. It signals the FDA’s recognition that MELAS syndrome presents a serious and unmet medical need and highlights the potential of sonlicromanol to become the first disease-modifying treatment for this devastating mitochondrial disease”.

A Phase IIb study (KHENERGYZE) of sonlicromanol in MELAS spectrum disorders is currently ongoing across a number of internationally recognised mitochondrial disease centres in Europe. Khondrion intends to submit a pre-IND (Investigational New Drug) request in the short term to further discuss the development plan for sonlicromanol in the US.

Source: Khondrion

Posted: September 2020

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Articles You May Like

Childhood cancer survivors at greater risk of ill health
Pfizer COVID Vaccine Is 100% Effective in Adolescents: Study
Targeted drug recommended to treat some advanced lung cancer patients
Versatile low light barcode reader
A Direct Recommendation From A Doctor May Be The Final Push Someone Needs To Get Vaccinated

Leave a Reply

Your email address will not be published. Required fields are marked *